Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

BYM-338 receives FDA breakthrough therapy designation

Aug. 21, 2013

Mallinckrodt submits results from PK study requested by FDA in response to Pennsaid 2% NDA

Aug. 16, 2013

U.K.'s MRC supports Cyclacel's seliciclib study in RA

Aug. 14, 2013

First human implantation of map3 cellular allogeneic bone graft completed

Aug. 13, 2013

PTC Therapeutics selects candidate for spinal muscular atrophy collaboration

Aug. 9, 2013

Researchers at Genosco and Oscotec synthesize novel SYK inhibitors

Aug. 8, 2013

Isis Pharmaceuticals reports data from phase II ISIS-CRPRx study

Aug. 6, 2013

ReGenX Biosciences and Audentes Therapeutics to develop NAV vector treatments

Aug. 2, 2013

Phase IIa rheumatoid arthritis study planned for RHB-104

Aug. 1, 2013

Novartis receives positive CHMP opinion for Ilaris in systemic juvenile idiopathic arthritis

July 31, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....
BIO 2026: Alternatives to funding orphan drugs
BioWorld
At the BIO International Convention, nonprofit and for-profit companies discussed ways to fund orphan drug development, especially for ultra-rare diseases where...
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...